{"groups":[{"description":"Thalidomide (Thal) + Zolendronic acid (ZLD)","id":"FG000","title":"Arm I: Thal/ZLD"},{"description":"Zoledronic acid (ZLD)","id":"FG001","title":"Arm II: ZLD"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"35"},{"groupId":"FG001","numSubjects":"33"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"32"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"All 68 participants were randomized.","recruitmentDetails":"Sixty-eight (68) participants were recruited at Mayo Clinic (Rochester) and Memorial Sloan-Kettering between July 2003 and March 2009."}